Videos

Specialty care approaches shared decision-making differently, and the stakes extend beyond a single symptom. The panel closes this discussion by debating whether treating agitation can shift disease trajectory itself.

With two on-label options now available, the choice between them comes down to comorbidities, psychosis, and risk. The panel also examines how long-term care rating pressures complicate that decision in practice.

Episode 3 of Gray Areas features a conversation with KuangHua Guo, MD, PhD, discussing the evolving debate around whether sleep disorders directly cause neurodegenerative disease and what the current evidence actually shows.

The panelists discuss the four-study development program for zorevunersen -- MONARCH, SWALLOWTAIL, ADMIRAL, and LONGWING -- describing how the clinical research was structured to assess dosing, safety, and both seizure and non-seizure outcomes in an exceptionally treatment-resistant patient population.

The panelists walk through the antisense oligonucleotide mechanism of zorevunersen, explaining how it targets the wild-type SCN1A allele to increase NaV1.1 protein production, and why this approach is uniquely suited to the genetics of Dravet syndrome.

The associate vice president of clinical research at the Parkinson's Foundation discussed new PD GENEration data validating a GBA1 intronic risk variant for Parkinson disease. [WATCH TIME: 6 minutes]

The chairman of the Neurology Service Line at Baptist Health in Kentucky discusses PREVAIL findings on clinical deterioration, rescue therapy use, and hospitalization with gefurulimab in generalized myasthenia gravis. [WATCH TIME: 3 minutes]

Longer follow-up and real-world claims data add context that pivotal trials alone cannot provide. The panel examines both, alongside how monitoring for response actually happens in daily practice.

A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this antipsychotic therapy was studied and what its data actually show.

The panelists discuss the critical shift from seizure-focused management to targeting the underlying genetic etiology of Dravet syndrome, drawing on natural history data that shows developmental impairment progresses independently of seizure control.

Three epileptologists set the stage on Dravet syndrome, exploring the biological underpinnings of the disease, the cascading burden it places on patients and families, and why this condition demands far more than seizure management.

The professor of neurology at the University of Cincinnati discussed how clinical awareness of social determinants and expanded telehealth have begun to move the needle for stroke care. [WATCH TIME: 7 minutes]

Neurology News Network for the week ending September 26th, 2026. [WATCH TIME: 4 minutes]

Episode 2 of Gray Areas features a conversation with Brian Callaghan, MD, MS, professor of neurology at the University of Michigan, discussing the clinical debate around whether diabetic peripheral neuropathy is reversible if diagnosed and treated early enough.

Safety data, not just efficacy, determines how comfortable clinicians feel prescribing. The panel reviews the safety profile, dosing schedule, and drug interactions relevant to a newer agitation therapy.

Pivotal trial data can reshape when clinicians feel comfortable starting treatment. The panel walks through the short- and long-term study results behind a newer agitation therapy in detail.

A duo of neurologists at Northwestern Medicine discussed the unmet needs in cluster headache and the diagnostic overlap with migraine that can delay care for patients. [WATCH TIME: 5 minutes]

Two on-label options are not enough for every patient. The panel weighs the field's remaining unmet needs against the biological rationale behind a newer, non-antipsychotic approach to treatment.

Decades of off-label prescribing for agitation associated with dementia due to Alzheimer’s are colliding with new evidence and new regulation. The panel examines why practice has lagged behind the data, and what is now changing.

Genetic testing is rapidly changing the evaluation of epilepsy, with some of its greatest diagnostic yield seen among children with seizures and developmental delay.

Moving from pediatric to adult epilepsy care can disrupt years of accumulated clinical knowledge, and Jacqueline French, MD, outlines how stronger handoffs and longitudinal records can help preserve continuity.

Neurology News Network for the week ending September 12th, 2026. [WATCH TIME: 5 minutes]

Before any prescription is written, non-pharmacologic strategies and a structured framework guide the panel's approach to agitation, alongside a biological explanation for why redirection so often fails.

Agitation does not stay contained to the patient. The panel examines the data linking agitation to caregiver burden, and the communication gaps that complicate coordinating care across specialties.

Episode 1 features a conversation with Ahmet Hoke, MD, PhD, of Johns Hopkins Medicine, discussing the clinical debate behind keeping animal models for neuropathy research vs switching to induced pluripotent stem cell models.

Beyond seizure control, Jacqueline French, MD, examines how clinicians can more proactively uncover psychiatric, cognitive, behavioral, sleep, and other comorbidities that shape the lives of patients with epilepsy.

In this episode, neurologist Jacqueline French, MD, outlines a practical approach to suspected epilepsy, including how clinical history, EEG, MRI, cell phone video, and prolonged monitoring can help establish and refine the diagnosis.

Neurology News Network for the week ending September 5th, 2026. [WATCH TIME: 5 minutes]

Agitation eventually affects nearly every patient with Alzheimer's disease, yet it rarely looks like simple aggression. The panel outlines how common it is, the many forms it takes, and why it so often goes unrecognized.

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel walks through the clinical differences and where formal screening scales genuinely fit into daily practice.